Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...
AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
In August, EPKINLY was first listed, with specific reimbursement criteria, in Ontario and Quebec, and is now publicly funded in almost all remaining provinces, including Nova Scotia, British ...
Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...
Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...
Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...
In that indication, the drug competes with AbbVie and Genmab’s rival CD20xCD3 bispecific Epkinly (epcoritamab), so moving it into the first relapse setting could hand Roche an advantage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback